ClinVar Miner

Submissions for variant NM_032444.4(SLX4):c.420G>T (p.Glu140Asp)

dbSNP: rs753015235
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001214372 SCV001386049 uncertain significance Fanconi anemia 2021-09-02 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with aspartic acid at codon 140 of the SLX4 protein (p.Glu140Asp). The glutamic acid residue is weakly conserved and there is a small physicochemical difference between glutamic acid and aspartic acid. This variant is present in population databases (rs753015235, ExAC 0.03%). This variant has not been reported in the literature in individuals affected with SLX4-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The aspartic acid amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Sema4, Sema4 RCV001214372 SCV002529342 uncertain significance Fanconi anemia 2021-08-19 criteria provided, single submitter curation
Fulgent Genetics, Fulgent Genetics RCV002497733 SCV002812120 uncertain significance Fanconi anemia complementation group P 2021-07-08 criteria provided, single submitter clinical testing
Ambry Genetics RCV003163636 SCV003902930 uncertain significance Inborn genetic diseases 2023-02-15 criteria provided, single submitter clinical testing The c.420G>T (p.E140D) alteration is located in exon 2 (coding exon 1) of the SLX4 gene. This alteration results from a G to T substitution at nucleotide position 420, causing the glutamic acid (E) at amino acid position 140 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.